iX Biopharma Ltd. (SGX:42C)
Singapore · Delayed Price · Currency is SGD 0.4050
-0.0050 (-1.22%)
Aug 28, 2026, 5:07 PM SGT
iX Biopharma Cash Flow Statement
Financials in millions SGD. Fiscal year is July - June.
Millions SGD. Fiscal year is Jul - Jun.
Operating Activities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Net Income | -7.99 | -10.14 | -10.79 | -9.62 | -4.6 |
Depreciation & Amortization | 0.73 | 0.85 | 0.86 | 0.89 | 1.01 |
Other Amortization | - | 0 | 0.01 | 0.04 | 0.05 |
Loss (Gain) From Sale of Assets | -0.06 | - | - | - | - |
Asset Writedown & Restructuring Costs | 0.37 | - | - | - | - |
Loss (Gain) From Sale of Investments | - | 0.01 | 2.51 | -1.74 | 3.26 |
Stock-Based Compensation | 2.08 | 0.03 | -0.85 | 0.86 | 1.38 |
Provision & Write-off of Bad Debts | 0.06 | - | 0.11 | - | - |
Other Operating Activities | -1.46 | 4.57 | 1.46 | 2.36 | 2.72 |
Change in Accounts Receivable | -0.37 | 0.08 | -0.11 | -0.85 | -0.23 |
Change in Inventory | -0.44 | 0.31 | -0.62 | -0.2 | -0.04 |
Change in Accounts Payable | -0.13 | 0.48 | 0.86 | 0.71 | -0.27 |
Change in Other Net Operating Assets | -0.28 | 0.06 | 0 | -0.12 | -0.16 |
Operating Cash Flow | -7.51 | -3.76 | -6.55 | -7.66 | 3.12 |
Operating Cash Flow Growth | - | - | - | - | - |
Investing Activities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Capital Expenditures | -0.12 | -0.2 | -0.27 | -0.7 | -0.2 |
Sale of Property, Plant & Equipment | - | - | 1.34 | - | - |
Sale (Purchase) of Intangibles | -0 | - | -0.01 | - | - |
Investment in Securities | - | - | - | - | -5.42 |
Investing Cash Flow | -0.12 | -0.2 | 1.06 | -0.7 | -5.62 |
Financing Activities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Long-Term Debt Issued | 0.54 | 1.51 | 2.03 | - | 1.4 |
Long-Term Debt Repaid | -1.72 | -1.05 | -1.02 | -0.99 | -1.02 |
Net Debt Issued (Repaid) | -1.17 | 0.46 | 1.01 | -0.99 | 0.37 |
Issuance of Common Stock | 23.1 | 3.25 | - | 2.73 | 9.62 |
Other Financing Activities | -0.45 | -0.59 | -0.29 | -0.31 | -0.2 |
Financing Cash Flow | 21.48 | 3.12 | 0.72 | 1.42 | 9.79 |
Net Cash Flow
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Foreign Exchange Rate Adjustments | -0.02 | 0.01 | - | -0.05 | 0.03 |
Net Cash Flow | 13.84 | -0.83 | -4.77 | -6.98 | 7.32 |
Free Cash Flow
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Free Cash Flow | -7.62 | -3.96 | -6.83 | -8.36 | 2.92 |
Free Cash Flow Growth | - | - | - | - | - |
Free Cash Flow Margin | -111.21% | -50.97% | -114.57% | -141.30% | 20.31% |
Free Cash Flow Per Share | -0.01 | -0.01 | -0.01 | -0.01 | 0.00 |
Levered Free Cash Flow | -4.46 | -1.86 | -5 | -6.58 | 3.76 |
Unlevered Free Cash Flow | -4.03 | -1.66 | -4.72 | -6.41 | 3.89 |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Cash Interest Paid | 0.51 | 0.68 | 0.32 | 0.27 | 0.2 |
Cash Income Tax Paid | -0.16 | -0.73 | -0.48 | -0.54 | -0.71 |
Change in Working Capital | -1.22 | 0.93 | 0.14 | -0.45 | -0.7 |